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Neurobiology of Disease
microRNA-33 Regulates ApoE Lipidation and Amyloid-
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Dysregulation of amyloid- (A) metabolism is critical for Alzheimer’s disease (AD) pathogenesis. Mounting evidence suggests that
apolipoprotein E (ApoE) is involved in A metabolism. ATP-binding cassette transporter A1 (ABCA1) is a key regulator of ApoE
lipidation, which affects A levels. Therefore, identifying regulatory mechanisms of ABCA1 expression in the brain may provide new
therapeutic targets for AD. Here, we demonstrate that microRNA-33 (miR-33) regulates ABCA1 and A levels in the brain. Overexpres-
sion of miR-33 impaired cellular cholesterol efflux and dramatically increased extracellular A levels by promoting A secretion and
impairing A clearance in neural cells. In contrast, genetic deletion of mir-33 in mice dramatically increased ABCA1 levels and ApoE
lipidation, but it decreased endogenous A levels in cortex. Most importantly, pharmacological inhibition of miR-33 via antisense
oligonucleotide specifically in the brain markedly decreased A levels in cortex of APP/PS1 mice, representing a potential therapeutic
strategy for AD.
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Introduction
Dysregulation of A peptide metabolism is hypothesized to ini-
tiate pathogenic cascades that lead to Alzheimer’s disease (AD)
(Haass and Selkoe, 2007). Therefore, strategies to regulate A
production and clearance are actively being pursued as AD ther-
apies. Apolipoprotein E (APOE) genotype is the strongest genetic
risk factor for AD, with the 4 allele acting as an AD risk factor,
whereas the 2 allele is protective (Kim et al., 2009a). Previous
studies have suggested that the main effect of APOE isoforms on
AD risk is via their effect on Ametabolism (Kim et al., 2009a). In
addition to APOE isoforms, alterations in ApoE protein levels
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Significance Statement
Brain lipid metabolism, in particular Apolipoprotein E (ApoE) lipidation, is critical to Ametabolism and Alzheimer’s disease
(AD). Brain lipid metabolism is largely separated from the periphery due to blood–brain barrier and different repertoire of
lipoproteins. Therefore, identifying the novel regulatory mechanism of brain lipid metabolism may provide a new therapeutic
strategy for AD. Although there have been studies on brain lipid metabolism, its regulation, in particular by microRNAs, is
relatively unknown. Here, we demonstrate that inhibition of microRNA-33 increases lipidation of brain ApoE and reduces A
levels by inducingABCA1.Weprovide aunique approach forAD therapeutics to increaseApoE lipidation and reduceA levels via
pharmacological inhibition of microRNA in vivo.
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and lipidation status have been shown to strongly influence A
metabolism (Kim et al., 2009a,b; Bien-Ly et al., 2012).
ApoE is a major cholesterol carrier in the brain (Kim et al.,
2009a). Mounting evidence has demonstrated that dysregulation
of cholesterol metabolism is implicated in AD pathogenesis (Kim
et al., 2009a; Di Paolo and Kim, 2011). ATP-binding cassette
transporter A1 (ABCA1) is a major cholesterol transporter that
transfers cellular cholesterol onto lipid-poor apolipoproteins and
regulates ApoE lipidation in the brain (Koldamova et al., 2014).
Several genetic association studies have suggested possible
association between polymorphisms in ABCA1 and AD risk
(Koldamova et al., 2010). Moreover, animal studies have demon-
strated that ABCA1 levels regulate A deposition in vivo (Hirsch-
Reinshagen et al., 2004; Wahrle et al., 2004, 2005, 2008;
Koldamova et al., 2005). Furthermore, several lines of in vitro
evidence support the critical role of ABCA1 in A production,
although how ABCA1 regulates A production remains to be
clarified (Koldamova et al., 2003; Sun et al., 2003; Kim et al.,
2007). Given its effects on ApoE and A metabolism, ABCA1 is
considered to be a promising therapeutic target for AD. There-
fore, identifying the regulatory mechanisms of ABCA1 expres-
sion in the brain may provide new therapeutic strategies for AD.
In this study, we address this critical gap in our understanding of
cerebral ABCA1 regulation.
Recently, microRNAs (miRNAs) have emerged as a new class
of therapeutic targets for various diseases, including neurodegen-
erative disorders (Nelson and Keller, 2007; He´bert et al., 2009).
Small noncoding miRNAs bind to their target mRNAs and re-
press the expression of target genes through translational repres-
sion and/or mRNA decay. Previously, we demonstrated that
ABCA1 expression is regulated by miR-33 in the periphery (Ho-
rie et al., 2010; Rayner et al., 2010, 2011a,b). Pharmacological
inhibition of miR-33 increased plasma high-density lipoprotein
cholesterol levels in mice (Horie et al., 2010; Najafi-Shoushtari et
al., 2010; Rayner et al., 2011a) and primates (Rayner et al., 2011b;
Rottiers et al., 2013), leading to a marked reduction of atheroscle-
rosis phenotypes. However, the physiological function of miR-33
in the CNS and whether miR-33 has any pathological role in AD
have never been investigated.
Importantly, miRNAs quite often show cell-type, tissue, and
species-specific regulation of their target genes due to the differ-
ences in their expression levels and the complexity of interaction
with their targets in different cellular contexts (Landgraf et al.,
2007; Jovicˇic´ et al., 2013). Therefore, it is critical to study miRNA
function in appropriate cell types and tissues. Given the species-
specific phenotypes, it is critical to study the roles of miRNA in
human cells particularly for therapeutic approaches. Here, we
demonstrated that miR-33 suppresses ABCA1 expression in
mouse and human neural cells. We also provide evidence that
overexpression of miR-33 increases extracellular A levels by
promoting A secretion in neuronal cells and impairing A
clearance in both neuronal and glial cells. In contrast, genetic
deletion of mir-33 in mice dramatically increases ABCA1 levels
and ApoE lipidation while decreasing endogenous A levels
in cortex. Most importantly, pharmacological inhibition of
miR-33 in the brain dramatically increases ABCA1 levels and
effectively reduces A levels in a transgenic mouse model of
A amyloidosis.
Materials andMethods
Animals and anti-miR-33 treatment. All procedures with animals fol-
lowed the guidelines of the institutional animal care and use committee
at Kyoto University and Washington University. We previously reported
the generation of the mir-33 knock-out mice (Horie et al., 2010). miR-33
(/) mice were killed at 16 weeks of age for analyses. Regulus Thera-
peutics provided 2-fluoro/methoxyethyl-modified, phosphorothioate-
backbone-modified anti-miR-33 (TGCAATGCAACTACAATGCAC)
and the mismatch control (TCCAATCCAACTTCAATCATC). Two-
month-old APPsw/PSEN19 (APP/PS1) transgenic mice overexpressing
Swedish mutant APP695 and human PSEN1 with an exon 9 deletion
(Jankowsky et al., 2004) were treated with 30 g/d of anti-miR-33 or
mismatch control for 4 weeks via intracerebroventricular infusion using
an osmotic pump (Alzet) implanted in the subcutaneous space of the
back. Cerebral cortical tissues were dissected out and frozen immedi-
ately. Female mice were used for all experiments.
qRT-PCR. Total RNAs were extracted from mouse cortical tissues us-
ing TRIzol Reagent (Invitrogen). For mRNA quantification, the ex-
tracted RNAs were reverse transcribed using the High Capacity cDNA
Reverse Transcription kit (Applied Biosystems). Quantitative PCR was
performed with Power SYBR Green PCR Master Mix (Applied Biosys-
tems) on an ABI 7500 (Applied Biosystems) using the default thermal
cycling program. For miR-33 quantification, the total RNAs were reverse
transcribed with miScript II RT kit using HiSpec buffer (QIAGEN).
Quantitative PCR was performed with miScript SYBR Green PCR kit
(QIAGEN) on an ABI 7500 (Applied Biosystems). Relative mRNA and
miRNA levels were calculated by comparative Ct method using GeneEx
5.3.2 (multiday analyses). GAPDH and U6 were used as normalization
controls for SREBF2 and miR-33, respectively. miR-33 levels in the body
were normalized with the total RNA amounts due to the high variation in
U6 levels among different tissues.
Luciferase assay. Luciferase assays were performed as previously de-
scribed (Kim et al., 2012). Briefly, Neuro2a mouse neuronal (N2a) cells
were plated at a density of 4  10 4 cells per well in a 96-well plate 1 d
before transfection; 0.12 g of psiCHECK-2-human ABCA1 3UTR lu-
ciferase reporter vector containing the entire 3UTR of ABCA1 mRNA
downstream of Renilla luciferase was transfected to the cells. After 8 h,
media were changed to fresh DMEM/10% FBS, and the cells were al-
lowed to recover overnight. At 24 h after the first transfection, the cells
were transfected again with miR-33 or negative control at a final concen-
tration of 75 nM for 24 h. Luciferase activity was measured using the
Dual-Glo Luciferase Assay System (Promega). Renilla luciferase activity
was normalized with the corresponding firefly luciferase activity. Each
transfection condition was performed in triplicate, and the experiments
were repeated twice.
A secretion assay. A secretion assays were performed as previously
described (Kim et al., 2012). Briefly, N2a-APPsw and H4-APPsw cells
were transfected with miR-33 or scrambled control (Insight Genomics)
together with or without mAbca1 open reading frame (ORF) plasmid as
indicated using Lipofectamine 2000 (Invitrogen). At 48 h after transfec-
tion, media were changed. At 6 h after media change, the cells and media
were collected for analyses. All experiments were performed in duplicate
or triplicate and repeated independently 3 times.
A clearance assay. Primary astrocytes were prepared as described pre-
viously (Kim et al., 2009b). Primary astrocyte cells were transfected with
miR-33 or scrambled control together with or without mAbca1 ORF
using Lipofectamine LTX (Invitrogen). At 48 h after transfection, cells
were incubated in fresh DMEM/F-12/N2/1 mM sodium pyruvate me-
dium containing 200 nM A40 for 24 h. A clearance assays with N2a and
H4 cells were performed with 20 nM A40 as previously described (Kim et
al., 2012). Media were applied for Western blot analysis of A. A levels
were normalized with total protein levels. All experiments were per-
formed in duplicate or triplicate and repeated independently 3 times.
A40 monomers were prepared as previously described (Kim et al.,
2012).
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A degradation assay. Astrocytes were transfected with miR-33 or
scrambled control. At 48 h after transfection, the cells were incubated in
fresh serum-free media. After 24 h incubation, conditioned media were
collected and were incubated with 200 nM of synthetic A40. After 24 h of
incubation, the remaining A40 levels in the media were analyzed by
Western blots. For extracellular A degradation with PBS-soluble frac-
tions from mir-33 knock-out or wild-type (WT) mice, 20 g of total
proteins from each fraction was incubated with 200 nM of synthetic A40
in 200l of DMEM/F-12 for the indicated times, and then the remaining
A40 levels were analyzed by Western blots.
Cholesterol efflux assay. Cholesterol efflux assays were performed as
described previously (Kim et al., 2012). N2a cells and astrocytes were
plated in 12-well plates at a density of 1  10 6 and 4  10 5 cells/well,
respectively, and transfected with miR-33 or scrambled control for 24 h.
Cells were then loaded with 0.5 Ci/ml 3H-cholesterol (PerkinElmer)
for an additional 24 h. Liver X receptor agonist TO901317 (Cayman
Chemical) was applied to the cells at 1 M for 12 h. Cells were then
washed twice with PBS and incubated with 2% fatty-acid free BSA
(Sigma) in media in the presence of acetyl-coenzyme A acetyltransferase
inhibitor (2 M) for 2 h before the addition of 50 g/ml human ApoE
(Leinco Technologies) in fatty-acid free BSA media. Supernatants were
collected after 6 h, and radioactivity was counted and expressed as a
percentage of total cell 3H-cholesterol content (total effluxed 3H-
cholesterol  cell-associated 3H-cholesterol). Experiments were re-
peated 3 times.
Western blot analysis. Western blots were performed as previously de-
scribed (Kim et al., 2009b, 2012). Cells were lysed in RIPA buffer (50 mM
Tris-HCl, pH 7.4, 150 mM NaCl, 0.25% deoxycholic acid, 1% NP-40,
0.1% SDS, and 1 mM EDTA) with protease inhibitor mixture (Roche).
Brain tissues were sequentially extracted with PBS and RIPA buffer with
protease inhibitor mixture. For SDS-PAGE, equal amounts of total
protein for each lysate were separated on 4%–20% TGX (Tris-Glycine
eXtended) gels (Bio-Rad). For native PAGE, proteins adjusted to equal
amounts of ApoE per lane were separated by 4%–20% TGX gels for 11 h
at 4°C under nondenaturing condition. After transferring proteins to
0.22 m pore size nitrocellulose membranes (Bio-Rad), blots were
probed with mouse anti-ABCA1 antibody (HJ1, D.M.H. laboratory),
rabbit anti-APP antibody (Invitrogen), goat-ApoE antibody (Meridian
Life Science), mouse anti-A antibody (82E1, IBL International), mouse
anti-actin antibody (AC-15, Sigma), or mouse anti-tubulin antibody
(Abcam) at room temperature for 2 h. CTFwas also detected with 82E1
antibody. 82E1 antibody was raised against A1–16 but does not react
with noncleaved APP (IBL International). After secondary antibody in-
cubation, membranes were developed using Lumigen TMA-6 ECL de-
tection kit (Lumigen).
Sandwich ELISA for A. ELISA for A was performed as previously
described (Kim et al., 2009b). Cortical tissues were lysed in 0.2% dieth-
ylamine/50 mM NaCl lysis buffer with EDTA-free protease inhibitor mix-
ture (Roche) by sonication, as previously described (Kim et al., 2008).
The lysates were centrifuged at 18,000 g for 30 min, and the superna-
tants were collected. The level of A was measured by sandwich ELISA.
HJ2 (anti-A35-40) and HJ7.4 (anti-A37-42) were used as capture an-
tibodies, and HJ5.1-biotin (anti-Ab13-28) was used as the detection an-
tibody. All antibodies were generated by the D.M.H. laboratory. The
specificity of A ELISA was validated with the brain tissue lysates from
APP knock-out mice. The levels of Awere normalized with the levels of
total protein.
Statistical analysis.To determine the statistical significance, we first tested
whether our datasets passed the equal variance test (Levene Median test) and
normality test (Kolmogorov–Smirnov test) using SigmaStat 3.5 software.
After confirmation that the data did not violate the assumptions of paramet-
ric testing, the data were analyzed with a two-tailed Student’s t test (Graph-
Pad Prism 5).
Results
miR-33 is highly enriched in the brain
Given the tissue-specific expression of miRNAs and their diverse
functions in different tissues (Landgraf et al., 2007), it is impor-
tant to determine the spatial expression pattern of a miRNA and
investigate its function in physiologically relevant cell types. We
first measured miR-33 expression among several tissues. Inter-
estingly, miR-33 is highly enriched in the brain (Fig. 1A) and is
widely expressed across multiple brain regions (Fig. 1B).
Many miRNAs show unique cell-type-specific expression pat-
terns in different neural cell types, such as neurons, astrocytes,
and microglia (Jovicˇic´ et al., 2013). To study miR-33 function in
relevant cell types, we next measured miR-33 expression in
mouse primary neural cells. miR-33 was expressed in all neural
cell types with relatively higher expression in neurons, compared
with glial cells (Fig. 1C). Therefore, we hypothesized that miR-33
may have a critical role in ABCA1 regulation and Ametabolism
in the brain.
miR-33 suppresses ABCA1 expression in the brain
To determine whether miR-33 directly binds to the 3UTR region
of ABCA1 mRNA in neural cells, we performed a luciferase assay
with the reporter construct containing the entire 3UTR of hu-
Figure 1. miR-33 is enriched in the brain. A, Relative expression levels of miR-33 in different mouse tissues. Endogenous levels of miR-33 were analyzed by qRT-PCR in different mouse tissues
from 3.5-month-old C57B6mice (n 3). Each level was represented as a percentage of liver.B, Relative expression of miR-33 in themouse brain. MaturemiR-33 levels were analyzed by qRT-PCR
andwerenormalizedwith correspondingU6 levels (n2). Data are shownas apercentageof hippocampus.C, Relative expression levels ofmiR-33 inprimary cells isolated frommicebrains.miR-33
levels were analyzed in mouse primary neurons, astrocytes, and microglia by qRT-PCR. Data are shown as a percentage of neurons (n 3). Values are mean SEM.
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man ABCA1 mRNA downstream of luciferase (Fig. 2A). miR-33
suppressed the luciferase activity, whereas LNA-based miR-33
inhibitor (referred to miR-33-I) increased luciferase expression
in N2a cells (Fig. 2B). To determine whether miR-33 regulates
ABCA1 expression in neural cells, we transfected synthetic
miR-33 or scrambled negative control to N2a and astrocytes.
miR-33 overexpression significantly suppressed ABCA1 expres-
sion in both cell types (Fig. 2C,D). These results demonstrated
that miR-33 directly suppresses ABCA1 expression by targeting
its 3UTR region.
Previously, we generated mir-33-deficient mice (Horie et al.,
2010) in which the mir-33 gene is ablated without altering the
expression of the mir-33 host gene, SREBF2 (Fig. 2E). In many
cases, miRNA knock-out mice showed no gross phenotype under
Figure 2. miR-33 suppresses ABCA1 expression in the brain. A, Schematic diagram of the conserved target sites of miR-33 in the 3UTR of ABCA1mRNA. Themir-33 gene is located within the
intron of Sterol regulatory element binding transcription factor 2 (SREBF2) gene. The genomic sequences aroundmir-33 are highly conserved in mammals. Themature sequence of miR-33 is shown
in redwithinpre-mir-33.miR-33has threepotential targeting sites in theABCA1. Blueunderlines indicate3UTR. *Conservednucleotides.B,miR-33directly targets the3UTRofABCA1mRNA. (n
6pergroup). Luciferase reporter assayswereperformedwith the reporter construct containing the full-length3UTRofhABCA1mRNAdownstreamofRenilla luciferase.Renilla luciferase activitywas
normalizedwith the corresponding firefly luciferase activity. C,D, miR-33 decreased ABCA1 levels in N2a cells (n 6) andmouse primary astrocytes (n 5). Cells were transfectedwithmiR-33 or
scrambled negative control (Ctl). At 48 h after transfection, cells were harvested for Western blot analyses. ABCA1 protein levels were normalized by actin levels and quantified as a percentage of
control.E,miR-33 is selectively deleted in cortex ofmiR-33 (/)micewithout altering the expressionof its host gene, SREBF2, in cortex.GAPDH levelswereused for normalization. Data are shown
as a percentage ofWT. F,G, ABCA1 levelswere increased in cortex ofmir-33 knock-outmice (miR-33 (/), n 5), comparedwithWTmice (miR-33 (/), n 5). ABCA1 levelswere analyzed
by Western blot at 4 months of age. Actin levels were used for normalization. Data are shown as a percentage of control, and values are mean SEM. **p	 0.01 (t test). ***p	 0.001 (t test).
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normal physiological conditions, possibly due to the functional
redundancy of multiple miRNAs for the same target gene (Ebert
and Sharp, 2012; Mendell and Olson, 2012). Importantly,
ABCA1 protein levels were strongly increased in cortex of
mir-33-deficient mice (miR-33 (/)), compared with WT mice
(miR-33 (/)) (Fig. 2F,G), suggesting that miR-33 plays a
dominant role in regulating cerebral ABCA1 expression even un-
der normal physiological conditions.
Deletion ofmir-33 gene increases ApoE lipidation in
the brain
Because ABCA1 transports cellular cholesterol onto apolipopro-
teins, we assessed whether miR-33 regulates lipid transport in
neural cells. We performed cholesterol efflux assays in N2a cells
and astrocytes using ApoE as a cholesterol acceptor. miR-33 sig-
nificantly decreased ApoE-mediated cholesterol efflux in both
N2a cells and astrocytes (Fig. 3A).
To determine whether mir-33 deletion increases ApoE lipida-
tion in the brain, we performed the native PAGE followed by
Western blot for ApoE with extracellular protein-enriched PBS-
soluble fractions. ApoE-containing lipoprotein particles from the
mir-33-deficient mice tended to be larger in size than the particles
from WT mice, indicating that inhibition of miR-33 increases
ApoE lipidation in the brain (Fig. 3B). Moreover, mir-33-
deficient mice had significantly less PBS-soluble ApoE levels in
cortex, compared with WT mice (Fig. 3C,D). Similar phenotypes
were observed in our previous study using ABCA1 transgenic
mice (Wahrle et al., 2008). Collectively, these data suggest that
miR-33 regulates ApoE lipidation as well as extracellular ApoE
levels in the brain.
miR-33 regulates A secretion and A clearance in
neural cells
We and others previously demonstrated that ABCA1 decreases A
secretion by inhibiting BACE1-mediated APP cleavage without af-
fecting BACE1 expression in neuronal cells (Sun et al., 2003; Kim et
al., 2012). To determine whether miR-33 modulates A secretion in
neuronal cells, we transfected N2a cells expressing Swedish mutant
amyloid precursor protein (APPsw) with miR-33 or scrambled con-
trol and then measured the secreted A levels in the media. miR-33
markedly decreased ABCA1 levels and increased the levels of intra-
cellular CTF, the cleavage product of APP by BACE1, and the se-
creted A (Fig. 4A,B). As expected from previous ABCA1 studies
(Sun et al., 2003; Kim et al., 2012), miR-33 did not affect the levels of
BACE1 (Ctl 100.0  1.774 vs miR-33 101.0  3.652, n  5, p 
0.8061). Similar results were observed in human H4 neuroglioma
Figure 3. miR-33 regulates lipidation and level of ApoE in the brain. A, miR-33 impaired cellular cholesterol efflux in N2a and astrocytes. N2a and astrocytes were transfected with miR-33 or
scrambled negative control for 24 h and then incubated the cells with radioactively labeled 3H-cholesterol. After 24 h, cells were incubated with human ApoE3 as a cholesterol acceptor. Data are
shown as a percentage of total cellular 3H-cholesterol content (total effluxed 3H-cholesterol cell-associated 3H-cholesterol). Values aremean SEM. **p	 0.01 (t test). ***p	 0.001 (t test).
n3.B,mir-33deletion increasedhighly lipidatedApoE-containingparticles. PBS-soluble fractionswere analyzedbynativePAGEandApoE-specificWesternblot. Total ApoE levels applied for each
lane were shown below. C, D, PBS-soluble apoE levels were decreased in mir-33-deficient mice, compared with WT. Extracellular protein-enriched PBS-soluble fraction from cortex of mir-33-
deficient (n 6) andWTmice (n 8) were analyzed byWestern blots. Total protein levels (Ponceau staining) were used for normalization. Data are shown as a percentage of control, and values
are mean SEM. ***p	 0.001 (t test).
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cells expressing APPsw transfected with
miR-33 (Fig. 4C,D). To determine whether
the increase of A levels by miR-33 was me-
diated by repressing ABCA1, we tested
whether the effect of miR-33 on A levels
could be rescued by the expression of miR-
33-resistant ABCA1. In the presence of
miR-33 resistant Abca1 without 3UTR
(Abca1ORF), miR-33 did not affect ABCA1
levels nor A levels in N2a cells expressing
APPsw, suggesting that miR-33 regulates
A secretion via modulating ABCA1, rather
than other genes (Fig. 4E,F).
In addition to its role in A secretion,
ABCA1 has been also shown to decrease
A levels by promoting extracellular A
clearance in both neurons and glial cells
(Jiang et al., 2008; Kim et al., 2012).
Therefore, we examined whether miR-33
regulates A clearance. Cells were first
transfected with miR-33 or scrambled
control and then incubated with synthetic
A. After 24 h of incubation, levels of A
remaining in the media were measured by
Western blot. We found that miR-33 dra-
matically impaired A clearance in N2a,
H4, and mouse primary astrocytes (Fig.
5A,B). Moreover, expression of miR-33-
resistant Abca1 ORF completely restored
the miR-33-mediated reduction of A
clearance in mouse primary astrocytes
(Fig. 5C,D). These data suggest that im-
pairment of A clearance by miR-33 was
mediated by ABCA1.
A previous report demonstrated that
extracellular Adegradation by proteases,
such as insulin-degrading enzyme, is in-
fluenced by the lipidation status of ApoE
(Jiang et al., 2008). Because miR-33 regu-
lates ApoE lipidation (Fig. 3A,B), we next
examined whether miR-33 could regulate
extracellular A degradation. After trans-
fecting miR-33 or scrambled control miR
to astrocytes, we collected conditioned
media for in vitro A degradation assay.
After incubating synthetic A40 in the
conditioned media for 24 h, we measured
the levels of A remaining in the media
using Western blot. Overexpression of
miR-33 significantly impaired A degradation in the astrocyte
conditioned media (Fig. 6A,B). To determine whether mir-33
deletion could affect extracellular A degradation, we performed
ex vivo A degradation assay using cerebral cortical tissue from
WT and mir-33-deficient mice. After incubating synthetic A40
in the extracellular protein-enriched PBS-soluble cortical tissue
homogenates, we measured the remaining A levels at different
time points. We found that mir-33 deletion significantly facili-
tated extracellular A degradation, compared with WT (Fig.
6C,D). Together, our data suggest that miR-33 regulates extracel-
lular A levels by modulating A secretion as well as A degra-
dation. Our data also imply that the role of miR-33 in regulating
ABCA1 and A levels is conserved in mouse and human neural
cells.
Inhibition of miR-33 effectively decreases A levels in
the brain
Given strong in vitro evidence that miR-33 regulates A levels in
neural cells, we next investigated whether inhibition of miR-33
decreases A levels in vivo. We first assessed whether mir-33 de-
letion decreases mouse endogenous A levels in the brain.mir-33
gene deletion markedly increased ABCA1 levels (Fig. 7A,B) and
decreased endogenous A40 levels by 33% and A42 levels by 40%
in cortex (Fig. 7C,D).
Next, we determined whether inhibition of miR-33 specifi-
cally in the brain can decrease human A levels in a mouse
model that produces human A in the brain (APP/PS1 mice).
Using 2-fluoro/methoxyethyl-modified- and phosphorothioate-
backbone-modified antisense miR-33 (denoted anti-miR-33)
Figure 4. Overexpression ofmiR-33 increases A secretion by suppressing ABCA1 in neural cells. Mouse N2a (A,B) and human
H4 cells (C, D) expressing APPsw were transfected with miR-33 or scrambled control. At 48 h after transfection, media were
changed to fresh serum-free media. At 6 h after media change, cells and media were collected for analyses. Intracellular ABCA1,
APP, andCTF levels and the secretedA levels in themediaweremeasuredbyWesternblots (n6per group). Actin levelswere
used for normalization. E, F, Overexpression of Abca1 ORF restored miR-33-mediated alteration of secreted A levels. Abca1 ORF
plasmidswere contransfectedwithmiR-33or scrambled control toN2a-expressingAPPsw, and the secretedA levels in themedia
were measured by Western blots (n 5 per group). Actin levels were used for normalization. Data are shown as a percentage of
control, and values are mean SEM. *p	 0.05 (t test). ***p	 0.001 (t test).
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(Rayner et al., 2011a,b), we treated
2-month-old APP/PS1 mice with anti-
miR-33 or mismatch negative control for
4 weeks via intracerebroventricular infu-
sion using osmotic pumps. Anti-miR-33
significantly increased ABCA1 protein
levels and decreased CTF levels in cor-
tex, compared with the mismatch control
(Fig. 8A,B). Importantly, anti-miR-33
therapy significantly decreased A40 levels
in cortex (Fig. 8C). There was also a trend
showing that anti-miR-33 decreased
A42 levels (24% difference between
means) (Fig. 8D). Collectively, these re-
sults demonstrated that inhibition of ce-
rebral miR-33 effectively reduces A
levels in vivo.
Discussion
Despite the critical role of Ametabolism
in AD pathogenesis, our understanding of
how endogenous A levels are regulated is
still limited. miRNAs have been identified
as a new class of regulatory molecules that
regulate many biological functions, in-
cluding pathogenesis of neurological dis-
eases. Although several in vitro studies
have implicated miRNAs in AD patho-
genesis, whether pharmacological inhibi-
tion of a miRNA can be a practical strategy
to regulate brain A levels in vivo has not
yet been demonstrated. For the first time,
we demonstrate here that genetic deletion
and pharmacological inhibition, using
antisense oligonucleotide, of miR-33 de-
creased A levels in the brain. In addition,
our study provides the first evidence that
miR-33 is an endogenous regulator of
ABCA1 in the brain and brain-specific
miR-33 antagonism may be an effective
strategy to modulate A levels.
miRNAs often show strong cell type-
and tissue-specific regulation of their tar-
gets (Landgraf et al., 2007; Jovicˇic´ et al.,
2013). Therefore, ABCA1 regulation by
miR-33 in the periphery does not neces-
sarily mean that miR-33 will regulate
ABCA1 in the brain. In our current study,
we demonstrated that miR-33 effectively
suppresses ABCA1 in the brain. miRNA
overexpression over a certain physiologi-
cal level may lead to an artificial effect by
surpassing biological buffering capacity of
the cells. Therefore, it is crucial to assess
the function of miRNA by modulating en-
dogenous miRNA levels. Somewhat unex-
pectedly, the vast majority of miRNA
knock-out mice examined thus far lack
any strong phenotypes under normal
physiological conditions (Ebert and
Sharp, 2012; Mendell and Olson, 2012).
This may be due to the functional redun-
dancy of many miRNAs in regulating the
Figure 5. Overexpression of miR-33 impairs A clearance in neural cells. A, B, Overexpression of miR-33 decreased A clear-
ance in neural cells. N2a, H4, and mouse primary astrocytes were transfected with miR-33 or scrambled control. At 48 h after
transfection, cells were incubatedwith synthetic A40monomers for 24 h. The remaining A40 levels in themediawere analyzed
byWestern blots (n5per group).C,D, Overexpression ofAbca1ORF restored the reduction of A clearance.Abca1ORFplasmids
were contransfectedwithmiR-33or scrambled control tomouseprimary astrocytes. At 48hafter transfection, cellswere incubated
with synthetic A40 monomers for 24 h. The remaining A40 levels in the media were analyzed by Western blots (n 4 per
group). Data are shown as a percentage of control, and values are mean SEM. **p	 0.01 (t test). ***p	 0.001 (t test).
Figure 6. miR-33 regulates extracellular A degradation. A, B, Overexpression of miR-33 impaired extracellular A degrada-
tion in the conditionedmedia fromastrocytes. Primary astrocyteswere transfectedwithmiR-33 or scrambled control. At 48 h after
transfection, conditioned media were collected and were incubated with 200 nM of synthetic A40. After 24 h of incubation, the
levels of A40 remaining in the media were analyzed by Western blots (n 3 per group). C, D, Deletion of miR-33 facilitated
extracellular A degradation in PBS-soluble fractions of cortices. PBS-soluble fraction of each mouse cortex was adjusted to the
sameamount of total proteins and then incubatedwith 200nMof synthetic A40 for the indicated time (n6per group). Data are
shown as a percentage of control, and values are mean SEM. ***p	 0.001 (two-way ANOVA).
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same target. In addition, low expression
levels of miRNAs in certain cell types and
tissues may partially account for the lack
of observable effects on their targets
(Jovicˇic´ et al., 2013). Here, we clearly
demonstrated that endogenous miR-33
suppresses ABCA1 expression under basal
condition by using mir-33-deficient mice
as well as inhibiting endogenous miR-33
specifically in the brain. Therefore, our
study suggests that miR-33 is a potent reg-
ulator of ABCA1 in the brain under nor-
mal physiological condition.
Although how ABCA1 regulates A lev-
els still remains unclear, several in vitro stud-
ies have suggested that ABCA1 inhibits A
secretion in neuronal cells by modulating
APP proteolysis and membrane lipid ho-
meostasis (Di Paolo and Kim, 2011). More-
over, we and others have shown that ABCA1
is required for the effective clearance of A
by neuronal and glial cells, and ApoE lipida-
tion by ABCA1 is critical for A clearance
(Jiang et al., 2008; Kim et al., 2012). In line
with these findings, we observed that
overexpression of miR-33 increased A se-
cretion in neuronal cells by increasing
-cleavage of APP. Moreover, overexpres-
sion of miR-33 impaired ApoE lipidation
and decreased A clearance by neuronal
and glial cells. In contrast, inhibition of
miR-33 in the brain significantly decreased
-cleavage of APP in APP/PS1 mice. More-
over, deletion of miR-33 increased ApoE
lipidation and facilitated extracellular A
degradation, leading to significant reduc-
tion of brain A levels, compared with WT.
We also demonstrated that the roles of
miR-33 in Ametabolism are conserved in
mouse and human neural cells. These data
suggest that miR-33 may represent a poten-
tial therapeutic target for AD by regulating
metabolism of ApoE and A.
Several miRNAs and antisense oligo-
nucleotides (ASOs) are currently under
investigation in clinical trials for various
diseases (Kanasty et al., 2013; van Rooij
and Kauppinen, 2014; Gaudet et al.,
2015). Pharmacological modulations of
disease-associated miRNAs appeared to
be well tolerated with promising out-
comes in animal models and human pa-
tients (van Rooij and Kauppinen, 2014).
In the current study, we demonstrated
that ASO-based pharmacological inhibi-
tion of miR-33 reduces A levels in the
brain after intracerebroventricular deliv-
ery of anti-miR-33 ASO. In clinical appli-
cation for brain diseases, blood– brain barrier is a major obstacle
in the delivery of small molecules into the brain. So far, no human
clinical trial demonstrated that an ASO can reduce the levels of a
target RNA or protein in the brain. However, it is noteworthy that
intrathecal ASO injection to nonhuman primates led to accumu-
lation of ASO in the cortical neuronal and glial cells (Rigo et al.,
2014). It will be interesting to determine whether intrathecal ASO
injection to human can also reproduce the similar data. Recently,
Figure 7. mir-33 deletion decreases mouse endogenous A levels in cortex. Compared with WT mice (n 8), ABCA1 levels
were dramatically increased in cortex ofmir-33 knock-outmice (n 7) at 4months of age, without altering APP levels (A,B). The
levels of A40 (C) andA42 (D) are significantly decreased in cortex ofmir-33 knock-outmice (n 7), comparedwithWT (n 9).
Actin levels were used for normalization ofWestern blots. A levels weremeasured by A-specific ELISA and normalized by total
protein levels. Data are shown as a percentage of control, and values are mean SEM. ***p	 0.001 (t test).
Figure 8. Brain-specific miR-33 inhibition decreases A levels in cortex of APP/PS1mice. Two-month-old APP/PS1mice were
treatedwith anti-miR-33 or themismatchnegative control for 4weeks via intracerebroventricular infusion. Anti-miR-33markedly
increased ABCA1 levels in cortex of APP/PS1mice (n 9), comparedwith themismatch control (n 6) (A,B). In the anti-miR-33
treatment group (n 9), A40 levels were significantly decreased ( p 0.0286) (C) and A42 levels showed a trend toward
decrease ( p 0.0954) (D), compared with the mismatch control (n 6). Actin levels were used for normalization of Western
blots. A levels were measured by A-specific ELISA and normalized by total protein levels. Data are shown as a percentage of
control, and values are mean SEM. *p	 0.05 (t test). ***p	 0.001 (t test).
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intrathecal ASO injection to human was successfully completed
in the Phase I and II clinical trials (Faravelli et al., 2015). Both
trials demonstrated that intrathecal ASO injection is safe and
effective. In addition, there have been substantial advances in the
small RNA delivery technology into the brain. For example,
conjugation with neurotrophic virus peptide and exosome- or
liposome-based nanoparticles are promising avenues of future
research (Kumar et al., 2007; Pulford et al., 2010; Alvarez-Erviti et
al., 2011; Roshan et al., 2014). In addition to ASOs, there have
been several successful cases that have identified small-molecule
modulators of miRNAs (Velagapudi et al., 2015), further expand-
ing the roles of miRNAs from diagnostic tools to therapeutic
targets of diseases. Therefore, further therapeutic developments
are warranted for the clinical application of miR-33 antagonism
for AD.
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